gsk201104136k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
 
 
For period ending April  2011
 
GlaxoSmithKline plc
(Name of registrant)

 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
Form 20-F x     Form 40-F
 
--
 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
Yes      No x
--
 
 

 
 

 


 

 
 
Notification of Transactions of Directors, Persons Discharging
 
 
Managerial Responsibility or Connected Persons
 
 
The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 12 April 2011 of an increase in their notional interests in Ordinary shares at a price of £12.22 per share and ADRs at a price of $39.96 per ADR following the notional re-investment of the dividend paid to shareholders on 7 April 2011.
 
 
Ordinary shares
ADRs
Mr A P Witty
5097.75
 
Dr M M Slaoui
 
1219.01
Mr S M Bicknell
158.12
 
Mr J M Clarke
1371.08
 
Mr M Dunoyer
516.38
 
Mr E J Gray
890.31
 
Mr S A Hussain
790.64
 
Mr W C Louv
 
441.67
Dr D Pulman
 
441.67
Mr D S Redfern
210.11
 
Mr J R Stéphenne
473.65
 
Ms C Thomas
158.12
 
Mr D E Troy
 
984.75
Dr P J T Vallance
652.78
 
Mrs V A Whyte
37.75
 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.
 
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a).
 
 
V A Whyte
 
 
Company Secretary
 
 
13 April 2011
 

 
 

 


 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


 
 
GlaxoSmithKline plc
(Registrant)

Date: April 13 2011
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc